Headline
The latest stories from AHA Today.
The Food and Drug Administration yesterday announced a firmware update to reduce the risk of rapid battery depletion and address cybersecurity vulnerabilities in certain Abbott devices that provide pacing for slow heart rhythms and electrical shock or pacing to stop dangerously fast heart rhythms.
Clinicians participating in the Merit-based Incentive Payment System may apply through April 30 to participate in a Centers for Medicare & Medicaid Services study on the burdens associated with reporting MIPS quality measures in 2018.
The AHA's Health Research & Educational Trust and Institute for Diversity and Health Equity have launched the 2018 Population Health, Equity and Diversity Survey.
Leaders of the Senate Health, Education, Labor and Pensions Committee today introduced bipartisan legislation to address the opioid crisis, which the committee will mark up on April 24.
The Food and Drug Administration today released a plan to improve medical device safety.
The American Society of Addiction Medicine and the American Medical Association yesterday released an issue brief on an alternative payment model for medication-assisted therapy, and seek physician practices and insurers interested in pilot testing the model for patients with opioid use disorder.
Current state proposals to require certain Medicaid beneficiaries to participate in work, training or other “community engagement” activity to remain eligible for coverage could affect more than 1.7 million enrollees and nearly $8 billion in program expenditures.
The Centers for Medicare & Medicaid Services plans to continue periodic post-payment reviews and provider education to ensure Medicare claims for telehealth services meet program requirements, and to ensure Medicare contractors implement all planned claims edits.
AHA Senior Vice President and Chief Medical Officer Jay Bhatt, D.O., yesterday participated in a panel on building a sustainable healthy community as part of the National Minority Quality Forum’s annual conference on health disparities.
The Drug Enforcement Administration continues to adjust manufacturers’ quotas for injectable opioid pain medications.